A plain language summary of two trials for larotrectinib in people with TRK fusion-positive lung cancer to learn how well the drug works and how safe it is

What is this summary about? This is a summary of a publication that reported data from participants in two clinical trials that studied a targeted cancer medicine called larotrectinib in a total of 20 participants with TRK fusion-positive lung cancer that had spread outside of the lungs. ‘TRK fusion-positive’ means that a patient’s lung cancer had a specific change in the gene called NTRK. The researchers wanted to know whether larotrectinib could shrink the participants’ tumors and what side effects it caused. What were the main results reported by the researchers? Researchers found that among the participants who took 100 milligrams (mg) of larotrectinib twice a day, 73% had their tumors respond to treatment, which means that their tumors shrank by over 30% or disappeared completely. 81% of the participants whose tumors responded to treatment continued to respond for 1 year. After 2 years, 65% continued to respond. The median time that participants’ tumors continued to respond to treatment was 33.9 months. The median is the middle number in a set of numbers when ordered from lowest to highest. In this case, the ‘median’ means that half of the participants continued to respond to treatment for more than 33.9 months. The median time that participants lived without their tumors growing was 35.4 months. This means that half of the participants lived without their tumors growing for more than 35.4 months. The median time that participants lived during the trials after starting treatment was 40.7 months. 80% of participants (16 out of 20) developed side effects. Most of these side effects were manageable. In this summary, side effects are the medical problems that happened during both trials that the researchers thought were possibly related to larotrectinib. The most common side effect was muscle aches. 10% of participants (2 out of 20) had severe side effects. The severe side effects were an overreaction by the immune system in response to treatment like an allergic reaction, an increase in body weight, and muscle aches. Severe side effects may cause medical problems that are significant enough to require medical attention or hospital care and may require a change in treatment dose.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2025-06-20
DOI
https://doi.org/10.1080/14796694.2025.2513212
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A plain language summary of two trials for larotrectinib in people with TRK fusion-positive lung cancer to learn how well the drug works and how safe it is

Víctor Moreno, Domnita-Ileana Burcoveanu, C. A. Ollis, Matthew Reiss et al.
Future Oncology
Lung Cancer Treatments and Mutations
article

A plain language summary of two trials for larotrectinib in people with TRK fusion-positive lung cancer to learn how well the drug works and how safe it is

Víctor Moreno, Domnita-Ileana Burcoveanu, C. A. Ollis, Matthew Reiss, Alexander Edward Dela Cruz Drilon, W. Marston Linehan, Oskar Torberger
article en

Abstract

What is this summary about? This is a summary of a publication that reported data from participants in two clinical trials that studied a targeted cancer medicine called larotrectinib in a total of 20 participants with TRK fusion-positive lung cancer that had spread outside of the lungs. ‘TRK fusion-positive’ means that a patient’s lung cancer had a specific change in the gene called NTRK. The researchers wanted to know whether larotrectinib could shrink the participants’ tumors and what side effects it caused. What were the main results reported by the researchers? Researchers found that among the participants who took 100 milligrams (mg) of larotrectinib twice a day, 73% had their tumors respond to treatment, which means that their tumors shrank by over 30% or disappeared completely. 81% of the participants whose tumors responded to treatment continued to respond for 1 year. After 2 years, 65% continued to respond. The median time that participants’ tumors continued to respond to treatment was 33.9 months. The median is the middle number in a set of numbers when ordered from lowest to highest. In this case, the ‘median’ means that half of the participants continued to respond to treatment for more than 33.9 months. The median time that participants lived without their tumors growing was 35.4 months. This means that half of the participants lived without their tumors growing for more than 35.4 months. The median time that participants lived during the trials after starting treatment was 40.7 months. 80% of participants (16 out of 20) developed side effects. Most of these side effects were manageable. In this summary, side effects are the medical problems that happened during both trials that the researchers thought were possibly related to larotrectinib. The most common side effect was muscle aches. 10% of participants (2 out of 20) had severe side effects. The severe side effects were an overreaction by the immune system in response to treatment like an allergic reaction, an increase in body weight, and muscle aches. Severe side effects may cause medical problems that are significant enough to require medical attention or hospital care and may require a change in treatment dose.

Future OncologyVol. 21(17)
Memorial Sloan Kettering Cancer Center (US), Harvard University (US), Massachusetts General Hospital (US), Go2 for Lung Cancer (US), Hospital Universitario Fundación Jiménez Díaz (ES), Bayer (Germany) (DE), National Patient Safety Foundation (US)
Good health and well-being
Openalex Percentile: Top 76%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.